Arup DebRoy

Dr. Arup DebRoy

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
PKPawan Kumar
Pawan Kumar
ARArindam Ray
Arindam Ray
ASAmrita Singh
Amrita Singh
ASAbida Sultana
Abida Sultana
RHRhythm Hora
Rhythm Hora
ADArup DebRoy
Arup DebRoy
Background: Globally, pneumonia claims the lives of about 700,000 children under the age of 5 every year. Pneumococcal conjugate vaccine (PCV) was introduced in India phase-wise, beginning in high-burden states, and the rollout was completed nationwide by 2021—representing a major initiative by the Ministry of Health and Family Welfare (MoHFW). Despite the challenges posed by the COVID-19 pandemic, the campaign succeeded in maintaining progress and achieving nationwide coverage. This narrative review highlights the significant decisions, processes, and coordinated efforts of the various stakeholders involved that led to this successful PCV rollout. Methodology: A comprehensive desk review of both published and unpublished literature relevant to pneumonia burden and the efficacy and effectiveness of PCVs, along with documentation of PCV introduction and the scale-up was carried out. Results: The documentation of the PCV journey has been broken down into four sections: pre-introduction, PCV Phase-I introduction, pan-India rapid expansion, and the period post-introduction. Since the nationwide rollout in 2021, PCV coverage in India has steadily increased, reflecting successful immunization efforts. WUENIC, which is an annual WHO, and UNICEF estimates of national immunization coverage also show a positive trend in vaccination coverage (PCV booster coverage = 25% (2021), rising to 83% (2023), aligning with the goals of the WHO and UNICEF’s Global Action Plan for the Prevention and Control of Pneumonia and Diarrhoea (GAPPD). Conclusions: The phased rollout was an ambitious effort by the MoHFW, which was particularly challenging given the overlap with the COVID-19 pandemic. Despite these hurdles, the MoHFW, along with strong collaboration from development partners and stakeholders, successfully navigated the complex rollout. Future studies on the role of PCVs in reducing antibiotic resistance and the economic benefits of PCV introduction could help policymakers sustain funding and prioritize vaccine procurement decisions.

9 September 2023 in Vaccine: X
Verified
Journal Article
Open access
SKSandeep Kumar
Sandeep Kumar
MMMercy Mvundura
Mercy Mvundura
ARArindam Ray
Arindam Ray
PHPradeep Haldar
Pradeep Haldar
PLPat Lennon
Pat Lennon
SRSachin Rewaria
Sachin Rewaria
• The study evaluated three new cold chain devices in India: electric, solar, passive. • All devices maintained correct temperatures but with a few excursions and failures. • A major benefit was helping establish new cold chain points in hard-to-reach areas. • Conditioning of ice blocks made the passive cooling device challenging to operate. • A key limitation for each device: the inability to freeze ice for vaccine carriers.

27 May 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
RMRashmi Mehra
Rashmi Mehra
ARArindam Ray
Arindam Ray
ASAmrita Singh
Amrita Singh
AKAmanjot Kaur
Amanjot Kaur
RHRhythm Hora
Rhythm Hora
ADArup DebRoy
Arup DebRoy
Background: Human papillomavirus (HPV) is a leading cause of cervical cancer. It has a substantial impact on global public health, with low- and middle-income countries, including India, facing the highest burden. In 2022, India reported 127,526 new cases and 79,906 deaths due to cervical cancer, projected to increase by 61% by 2040. Although the National Technical Advisory Group on Immunization recommended the HPV vaccine for cervical cancer prevention, it is yet to be a part of India’s universal immunization program. Objective: This study aims to examine online interest in the HPV vaccine in India from January 2010 to April 2024 using Google Trends. Methods: A cross-sectional analysis of Google Trends data was performed, using the relative search volume to track interest on a scale of 0‐100. Trends were analyzed annually using 1-way ANOVA and joinpoint regression to identify significant changes in search behavior related to public health events. Statistical significance was set at P<.05. Results: The average annual growth in HPV vaccine-related searches was 13.7% (95% CI 7.9%‐19.1%), with the highest relative search volume in 2024 (49.5) and the lowest in 2017 (3.38). Spikes in search interest aligned with key events like the 2018 National Technical Advisory Group on Immunization recommendation and the 2022 launch of the indigenous HPV vaccine. The results highlight online search data’s value in tracking public interest, which fluctuates in response to health policy changes or developments on social media. In India, targeted digital strategies will be vital for addressing vaccine hesitancy and increasing HPV vaccine uptake. Conclusions: Google Trends data can inform public health strategies by identifying periods of high interest, aiding in the promotion of HPV vaccination in India.

28 August 2025 in Discover Viruses
Verified
Journal Article
Open access
PDF file
SGSamiran Ghosh
Samiran Ghosh
DKDivya Kappara
Divya Kappara
NMNabanita Majumder
Nabanita Majumder
SNSuchita Nath-Sain
Suchita Nath-Sain
ADArup DebRoy
Arup DebRoy
SMSiuli Mukhopadhyay
Siuli Mukhopadhyay
Introduction Outbreaks of measles have been frequently reported despite the availability of an effective vaccine. In this systematic review we examine the potential factors that could impact the effectiveness, efficacy and immunogenicity of the measles vaccine (MV) in children. Methods We conducted a literature search using PubMed and Google Scholar for primary articles published between January 2010 and April 2025. Articles reporting the effectiveness, efficacy or immunogenicity of MV in children aged 0–15 years were included. Additionally, we use regression analysis on data available from few cohort studies in India and epidemiological modelling simulations to assess the effect of factors on vaccine effectiveness (VE), efficacy and immunogenicity. Results Overall, 48 primary articles involving 172,464 children who had received the MV were included in the analysis. Key factors that may affect VE, efficacy and immunogenicity were malnutrition, genetic variants, chemotherapy and gender. Through statistical modelling we identified an inverse relationship between malnutrition and measles VE and estimated the possible percentage decrease in VE due to malnutrition across different states of India. Additionally, simulations from a Susceptible-Infected type model showed the effect of varying VE on the modelling outcomes and measles elimination targets. Conclusions We identified a few key factors including malnutrition, genetic variants, chemotherapy and gender that impact measles VE, efficacy and immunogenicity. Therefore, in addition to maintaining WHO recommended vaccine coverages, addressing the problems related to vaccine performance, evaluated in terms of VE, efficacy and immunogenicity, is crucial for achieving measles elimination targets.

20 March 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
PKPawan Kumar
Pawan Kumar
RMRashmi Mehra
Rashmi Mehra
ARArindam Ray
Arindam Ray
ASAmrita Singh
Amrita Singh
KSKapil Singh
Kapil Singh
ADArup DebRoy
Arup DebRoy
Introduction: In 2023, India’s National Technical Advisory Group on Immunization (NTAGI) recommended the inclusion of typhoid conjugate vaccine (TCV) in the Universal Immunization Programme (UIP). However, introducing TCV, an additional injectable vaccine (AIV), will potentially increase the number of injections administered in a single visit to a maximum of five (if given at the 9 to 12 months touchpoint) or four (if given in the second year of life). In this context, the present study aimed to explore the perspectives of program managers, service providers, and caregivers regarding introduction of an AIV in a single visit under the UIP. Methods: A mixed-method study was undertaken wherein quantitative data was collected by telephonic surveys, and qualitative data by key informant interviews (KIIs) and focus group discussions (FGDs). Purposive sampling encompassed eight states, eight districts, eight planning units, and 32 session sites. The qualitative data were thematically analyzed manually using Excel, while the quantitative data was analyzed using STATA 17. Results: A total of 1140 telephonic surveys, 96 KIIs, and 16 FGDs were conducted. The study revealed that program managers mentioned maternal emotional reactions as a significant concern and backed AIV introduction at the 9–12 months touchpoint. Vaccinators and community mobilizers favored the 16–24 months window with combined presentations and mentioned single-dose vials as the preferred approach for vaccine delivery. Caregivers acknowledged the benefits of vaccination but expressed discomfort and fear regarding multiple injections to the child in a single visit. Caregivers expressed a preference for a combination vaccine. No preference was reported among caregivers for the introduction of AIV to the 9–12 or 16–24 months touchpoints. Conclusion: Stakeholders’ perspectives on introducing an additional injectable vaccine in a single visit under the UIP are diverse. These will be helpful in developing an effective strategy for the future introduction of AIV under UIP.

12 May 2023 in Vaccine
Verified
Journal Article
Open access
TGTarun K. George
Tarun K. George
NNNayana P. Nair
Nayana P. Nair
ASAwnish Kumar Singh
Awnish Kumar Singh
AKA. Dilesh Kumar
A. Dilesh Kumar
ADArup DebRoy
Arup DebRoy
GKGagandeep Kang
Gagandeep Kang
Background: Vaccines were crucial in controlling the Covid-19 pandemic. As more vaccines receive reg-ulatory approval, stakeholders will be faced with several options and must make an appropriate choice for themselves. We proposed a multi-criteria decision analysis (MCDA) framework to guide decision -makers in comparing vaccines for the Indian context. Methods: We adhered to the ISPOR guidance for the MCDA process. Seven vaccine options were com-pared under ten criteria. Through three virtual workshops, we obtained opinions and weights from citi-zens, private-sector hospitals, and public health organisations. Available evidence was rescaled and incorporated into the performance matrix. The final score for each vaccine was calculated for the different groups. We performed different sensitivity analyses to assess the consistency of the rank list. Results: The cost, efficacy and operational score of the vaccines had the highest weights among the stake-holders. From the six scenario groups, Janssen had the highest score in four. This was driven by the advantage of having a single dose of vaccination. In the probabilistic sensitivity analysis for the overall group, Covaxin, Janssen, and Sputnik were the first three options. The participants expressed that avail-ability, WHO approvals and safety, among others, would be crucial when considering vaccines. Conclusions: The MCDA process has not been capitalised on in healthcare decision-making in India and LMICs. Considering the available data and stakeholder preference at the time of the study, Covaxin, Janssen, and Sputnik were preferred options. The choice framework with the dynamic performance matrix is a valuable tool that could be adapted to different population groups and extended based on increasing vaccine options and emerging evidence. *ISPOR - The Professional Society for Health Economics and Outcomes Research.(c) 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).